Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium

Merck announced that data across multiple genitourinary cancers from several approved and investigational medicines will be presented at the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium from Feb. KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) 1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. KEYTRUDA, As a single agent, is indicated to the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA- authorized test, with disease progression on or after platinum-containing chemotherapy.

Patients with EGFR or ALK genomic tumors aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. Microsatellite Instability-High or Mismatch Repair Deficient Cancer: KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA- authorization test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. KEYTRUDA is indicated For the treatment of patients with unresectable and metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA- authorize test.

Gastric Cancer: KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first -line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD- LITESPARK-011 data highlight the disease-free survival benefit of WELIREG in combination with LENVIMA®? (lenvatinib), respectively. All three studies will be featured in the official ASCO GU Press Program.